Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer
NCT05969899
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Cancer
Interventions
DRUG:
FOLFIRI+Bevacizumab
Sponsor
Fudan University